Last reviewed · How we verify

NCT05117606: LYNG21

LYNG21: Ably LYNG Clinical Demonstration in Operative Environment

Status unknown NA Last updated 11 November 2021
What this trial tests

NA trial testing LYNG by Ably Medical in Monitoring, Physiologic in 20 participants. Status unknown.

Timeline
25 May 2021
Primary endpoint
1 December 2021
31 December 2021

Quick facts

Lead sponsorAbly Medical AS
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment20
Start date25 May 2021
Primary completion1 December 2021
Estimated completion31 December 2021
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Ably Medical AS

Who can join

18 and older, any sex, with Monitoring, Physiologic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study main objective will be to compare measurements of heart rate, respiration rate, blood pressure and movement done by LYNG by Ably Medical with the corresponding measurements made by standard equipment in a patient sample in a hospital setting. The comparison will show the degree of agreement between LYNG and the existing current standard equipment. Data from the study will support Ably Medical in optimizing the LYNG product and measurement precision.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Monitoring, Physiologic

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05117606.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing